YUNNAN BAIYAO GROUP CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.15 CNY | -0.06% |
|
-0.80% | +4.07% |
| 12/06 | Yunnan Baiyao Group Co.,Ltd Announces Board Appointments | CI |
| 06/06 | Yuyue Medical Owners Prohibited from Leaving China for Alleged Links to Baiyao Corruption Case | MT |
ETFs positioned on Yunnan Baiyao Group Co.,Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.68% | 1 M€ | -23.55% | - | |
| 1.32% | 2 M€ | -14.14% | ||
| 1.18% | 4 M€ | -2.96% | ||
| 0.13% | 35 M€ | -5.85% | - | |
| 0.11% | 2 M€ | -2.29% | - | |
| 0.10% | 4 M€ | -11.56% | ||
| 0.05% | 11 M€ | +6.33% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.01% | 152 M€ | +7.71% | - | |
| 0.01% | 451 M€ | +8.79% | - | |
| 0.01% | 2,838 M€ | +11.35% | - | |
| 0.01% | 114 M€ | +5.50% | - | |
| 0.00% | 35 M€ | +4.82% | - | |
| 0.00% | 7 M€ | +3.51% | - | |
| 0.00% | 32 M€ | +4.52% | - | |
| 0.00% | 36 M€ | +10.49% | - | |
| 0.00% | 414 M€ | +12.00% | - | |
| 0.00% | 40 M€ | +7.33% | - | |
| 0.00% | 324 M€ | +8.15% | - |
Yunnan Baiyao Group Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical products. The group proposes primarily traditional medicine products, phytobiological products, body care products, antibiotics and anti-inflammatory.
China accounts for 98.9% of net sales.
Sector
Pharmaceuticals
Calendar
29/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
51.15
CNY
Average target price
65.01
CNY
Spread / Average Target
+27.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.07% | 12.56B | |
| +55.32% | 815B | |
| +44.05% | 641B | |
| -6.75% | 352B | |
| +13.56% | 314B | |
| +10.68% | 303B | |
| +16.57% | 242B | |
| +13.31% | 218B | |
| +8.48% | 168B | |
| -2.81% | 159B |
- Stock Market
- Equities
- 000538 Stock
- Funds and ETFs Yunnan Baiyao Group Co.,Ltd
